tiprankstipranks
TScan Therapeutics (TCRX)
NASDAQ:TCRX
US Market
TCRX
TScan Therapeutics
RESEARCH TOOLSreports
Want to see TCRX full AI Analyst Report?

TScan Therapeutics (TCRX) Income Statement

365 Followers

TScan Therapeutics Income Statement

Last quarter (Q4 2025), TScan Therapeutics's total revenue was $2.57M, an increase of 286.02% from the same quarter last year. In Q4, TScan Therapeutics's net income was $-22.98M. See TScan Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 10.32M$ 2.82M$ 21.05M$ 13.54M$ 10.14M
Gross Profit
$ 7.46M$ 2.82M$ 21.05M$ 13.54M$ 10.14M
Operating Expenses
$ 143.27M$ 137.64M$ 114.51M$ 80.17M$ 58.78M
Depreciation and Amortization
$ 2.87M$ 4.11M$ 5.36M$ 5.14M$ 3.33M
EBITDA
$ -132.95M$ -119.74M$ -80.10M$ -59.91M$ -45.30M
Operating Income
$ -135.81M$ -134.82M$ -93.46M$ -66.64M$ -48.64M
Other Income/Expenses
$ 6.05M$ 7.32M$ 4.24M$ 415.00K$ 16.00K
Pretax Income
$ -129.77M$ -127.50M$ -89.22M$ -66.22M$ -48.63M
Net Income
$ -129.77M$ -127.50M$ -89.22M$ -66.22M$ -48.63M
Per Share Metrics
Basic EPS
$ -1.00$ -1.14$ -1.36$ -2.74$ -2.03
Diluted EPS
$ -1.00$ -1.14$ -1.36$ -2.74$ -2.03
Weighted Average Shares Outstanding
 129.86M 111.99M 65.60M 24.05M 23.91M
Weighted Average Shares Outstanding (Diluted)
 129.86M 111.99M 65.60M 24.05M 23.91M
Currency in USD

TScan Therapeutics Earnings and Revenue History